| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/18/2003 | US20030175849 Identifying compounds for treating vision defects associated with intraocular pressure |
| 09/18/2003 | US20030175834 Polyphenol inhibition of nucleoside diphosphate kinase-B activity and cancer metastasis |
| 09/18/2003 | US20030175833 Packaged pharmaceuticals and methods for causing compounds and pharmaceutical compositions to be used as inhibitors of neoplastic lesions |
| 09/18/2003 | US20030175832 Diagnosing nervous system disorder via presence of aberrant macrophages in blood |
| 09/18/2003 | US20030175822 Opiate, cannabinoid, and estrogen receptors |
| 09/18/2003 | US20030175775 Ligand for G-protein coupled receptor GPR43 and uses thereof |
| 09/18/2003 | US20030175766 Therapy and diagnosis of conditions related to telomere length and/or telomerase activity |
| 09/18/2003 | US20030175745 Peptides with growth inhibitory action |
| 09/18/2003 | US20030175739 Nucleic acids, proteins, and antibodies |
| 09/18/2003 | US20030175731 Hybrid immunomodulatory peptide and nucleotide sequences for treating allergies |
| 09/18/2003 | US20030175680 Methods of treating and preventing bone loss |
| 09/18/2003 | US20030175396 Sugar-free products with improved characteristics |
| 09/18/2003 | US20030175373 Osteoporosis therapy; plant extract |
| 09/18/2003 | US20030175372 Resveratol; plant extracts |
| 09/18/2003 | US20030175366 Plant Extracts and Methods of Treating Skin Therewith |
| 09/18/2003 | US20030175363 Pharmaceutical composition and process for isolation of trans-tetracos-15-enoic acid and method of treatment for hepatotoxicity |
| 09/18/2003 | US20030175362 Disinfecting nitrous acid compositions and process for using the same |
| 09/18/2003 | US20030175361 Using selenium in combination with drugs used conventionally to treat psychiatric or neurological disorders |
| 09/18/2003 | US20030175360 Comprising locally acting anesthetic, and an antacid; treatment of gastroesophageal reflux disease |
| 09/18/2003 | US20030175357 Prolonged anesthesia in joints and body spaces |
| 09/18/2003 | US20030175356 Use of biodegradable microspheres that release an anticancer agent for treating gliobastoma |
| 09/18/2003 | US20030175355 Fast melt multiparticulate formulations for oral delivery |
| 09/18/2003 | US20030175353 Comprises carbamazepine and one or more hydrophobic polymers in homogenous admixture, wherein system does not comprise means capable of preventing conversion of carbamazepine to its dihydrate form |
| 09/18/2003 | US20030175352 Having a plurality of solid, polymeric matrix beads comprising considerable amounts of greasy/oily/sticky substances and having fast release characteristics; drug delivery |
| 09/18/2003 | US20030175351 Pharmaceutical composition for oral use with improved absorption |
| 09/18/2003 | US20030175348 Novel pharmaceutical formulation with controlled release of active substances |
| 09/18/2003 | US20030175345 Isoflavone composition for oral delivery |
| 09/18/2003 | US20030175344 Comprising diuretic, beta blocker, angiotensin converting enzyme inhibitor, angiotensin II receptor antagonist, calcium channel blocker, lipid-regulating agent, platelet function altering agent, serum homocysteine lowering agent |
| 09/18/2003 | US20030175343 Controlled release pharmaceutical composition containing tramadol hydrochloride |
| 09/18/2003 | US20030175342 Coated pharmaceutical single-unit delayed-release forms, based on polyvinyl acetate |
| 09/18/2003 | US20030175340 Antiulcer agents (H2-antagonists such as ranitidine and cimetidine); for treating osteoporosis |
| 09/18/2003 | US20030175339 Formed by direct compression; friability |
| 09/18/2003 | US20030175338 Formulations of atorvastatin stabilized with alkali metal additions |
| 09/18/2003 | US20030175337 For treatment of thyroid disorders; hormone replacement therapy |
| 09/18/2003 | US20030175336 Soft tablet containing high molecular weight polyethylene oxide |
| 09/18/2003 | US20030175334 Phospholipid bodies and use thereof in medical treatment |
| 09/18/2003 | US20030175333 Invisible patch for the controlled delivery of cosmetic, dermatological, and pharmaceutical active ingredients onto the skin |
| 09/18/2003 | US20030175332 Administering oligosaccarhides, polysaccharides, and/or glycoaminoglycans for treatment of diseases/conditions associated with allergies, autoimmunity, the adhesion cascade, or metastasis |
| 09/18/2003 | US20030175331 Pressure sensitive adhesive comprising isoprene-styrene block copolymer/tackifier resin and diclofenac sodium |
| 09/18/2003 | US20030175329 Semisolid topical hormonal compositions and methods for treatment |
| 09/18/2003 | US20030175328 Patch for the controlled delivery of cosmetic, dermatological, and pharmaceutical active ingredients into the skin |
| 09/18/2003 | US20030175327 Comprises crosslinked dextran-alginate spheres/beads on cotton gauze |
| 09/18/2003 | US20030175326 Palatable controlled-release formulations for companion animals |
| 09/18/2003 | US20030175315 Nanoemulsion comprising metabolites of ginseng saponin as an active component and a method for preparing the same, and a skin-care composition for anti-aging containing the same |
| 09/18/2003 | US20030175314 Pharmaceutical composition for dermal application |
| 09/18/2003 | US20030175313 Preparation of sterile stabilized nanodispersions |
| 09/18/2003 | US20030175310 A pure immunogenic polypeptide for producing polyclonal and monoclonal antibodies |
| 09/18/2003 | US20030175282 Photodynamic therapy comprising administering angiogenesis factor antagonists and photosensitizers then irradiating with lasers, for prophylaxis of vision defects |
| 09/18/2003 | US20030175269 Light and heavy chain peptides, used as antagonists of CD antigen or membrane proteins, for prophylaxis of autoimmune diseases |
| 09/18/2003 | US20030175267 Method for the treatment of inflammatory joint disease |
| 09/18/2003 | US20030175259 Use of corneal hardening agents in enzymeorthokeratology |
| 09/18/2003 | US20030175258 Mixing shoots of Pinaceae plants with water and saccharides followed by spontaneous fermenting with yeasts to form remedies for allergic diseases; side effect reduction; for treatment of asthma, atopic dermatitis |
| 09/18/2003 | US20030175244 Capsid-modified recombinant adenovirus and methods of use |
| 09/18/2003 | US20030175237 Method for the reduction of fasting plasma glucose and hemoglobin AIC levels |
| 09/18/2003 | US20030175236 Fat-binding polymers |
| 09/18/2003 | US20030175231 Contacting epidermal melanocytes with a peptide having amino acid sequence lysine-glycine- alanine to inhibit cell loss, which binds to p75 nerve growth factor receptor expressed on the surface of the melanocytes |
| 09/18/2003 | US20030175215 A beverage for prevention of tooth damage by plaque acid production; a carbohydrate drink or candy comprising maltodextrin and less than 1.0% of mono- and di-saccharides |
| 09/18/2003 | US20030175214 Free-flowing fine particle mixtures comprising carrier particles, active drug particles and stabilizer particles, for respiratory system disorders; medical equipment |
| 09/18/2003 | US20030175205 Comprising a radioactive materials for detecting and/or quantifying diseases or conditions associated with cancer, infections, inflammation; a 2-propane carboxylic ester with a attached phosphatidic acid group |
| 09/18/2003 | US20030172924 Medicament storage and delivery devices |
| 09/18/2003 | CA2813780A1 Genetic products differentially expressed in tumors and use thereof |
| 09/18/2003 | CA2671976A1 Methods of inducing terminal differentiation |
| 09/18/2003 | CA2482191A1 Spiro compounds with npy antagonistic activity |
| 09/18/2003 | CA2481371A1 Use of ppar alpha agonists for the treatment of vascular and renal diseases |
| 09/18/2003 | CA2480001A1 Chain oligolactic acid thioester |
| 09/18/2003 | CA2479071A1 Process for producing optically active sulfoxide derivative |
| 09/18/2003 | CA2479065A1 Aminoalcohol derivatives as beta-3 adrenergic receptor agonists |
| 09/18/2003 | CA2479036A1 Aryl substituted pyrimidines and the use thereof |
| 09/18/2003 | CA2479027A1 A non-hormonal approach to male contraception |
| 09/18/2003 | CA2479016A1 Quinazoline compounds useful in therapy |
| 09/18/2003 | CA2478958A1 Use of proton pump inhibitors for the treatment of airway disorders |
| 09/18/2003 | CA2478948A1 5-}2-hydroxy-3-`1-(3-trifluoromethylphenyl)-cyclopropyl!-propionylamino}-phtalide and related compounds with progesterone receptor modulating a ctivity for use in fertility control and hormone replacement therapy |
| 09/18/2003 | CA2478945A1 Cyclic amides |
| 09/18/2003 | CA2478942A1 An optically active pyridine derivative and a medicament containing the same |
| 09/18/2003 | CA2478936A1 Monocyclic aroylpyridinones as antiinflammatory agents |
| 09/18/2003 | CA2478931A1 A method of treating diabetes mellitus including conditions associated with diabetes mellitus and complications of diabetes mellitus |
| 09/18/2003 | CA2478921A1 Novel chalcone derivatives and uses thereof |
| 09/18/2003 | CA2478897A1 Compounds capable of inhibiting immunocyte-related allergic immune reactions |
| 09/18/2003 | CA2478827A1 Remedies for sex hormone-dependent disease |
| 09/18/2003 | CA2478765A1 Bicyclic heterocycles for the treatment of diabetes and other diseases |
| 09/18/2003 | CA2478706A1 Oxo-azabicyclic compounds |
| 09/18/2003 | CA2478701A1 Derivatives of 4-(imidazol-5-yl)-2-(4-sulfoanilino) pyrimidine with cdk inhibitory activity |
| 09/18/2003 | CA2478685A1 Ophthalmic solutions containing tetrazole derivatives |
| 09/18/2003 | CA2478652A1 Nitrosodiphenylamine derivatives and their pharmaceutical use against oxidative stress pathologies |
| 09/18/2003 | CA2478600A1 Antiparasitic artemisinin derivatives (endoperoxides) |
| 09/18/2003 | CA2478599A1 Salts of nateglinide |
| 09/18/2003 | CA2478592A1 Genomic screen for epigenetically silenced genes associated with cancer |
| 09/18/2003 | CA2478589A1 Nematicidal fatty acid and fatty acid ester related compounds |
| 09/18/2003 | CA2478522A1 Novel curcuminoid-factor viia constructs as suppressors of tumor growth and angiogenesis |
| 09/18/2003 | CA2478510A1 Genomic screen for epigenetically silenced tumor suppressor genes |
| 09/18/2003 | CA2478479A1 Methods, compositions, and kits for enhancing oligonucleotide-mediated nucleic acid sequence alteration using compositions comprising a histone deacetylase inhibitor, lambda phagebeta protein, or hydroxyurea |
| 09/18/2003 | CA2478412A1 Inhibitors of the blood-clotting factor xa, production thereof and use of the same |
| 09/18/2003 | CA2478342A1 Heterocyclic amide derivatives for the treatment of diabetes and other diseases |
| 09/18/2003 | CA2478338A1 Combination therapy for treating, preventing or managing proliferative disorders and cancers |
| 09/18/2003 | CA2478317A1 Methods of preventing or treating disorders by administering an integrin .alpha.v.beta.3 antagonist in combination with an hmg-coa reductase inhibitor or a bisphosphonate |
| 09/18/2003 | CA2478276A1 Azepane derivatives and their use as atk1 inhibitors |
| 09/18/2003 | CA2478245A1 Treatment and prevention of inflammatory disorders |
| 09/18/2003 | CA2478239A1 The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents |
| 09/18/2003 | CA2478177A1 Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist |
| 09/18/2003 | CA2478121A1 Antibiotic composition |